Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives $6.88 Consensus Price Target from Analysts

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $6.8750.

A number of analysts have issued reports on the company. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Alliance Global Partners assumed coverage on Sensus Healthcare in a report on Friday, March 6th. They issued a “buy” rating and a $7.50 target price on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a report on Tuesday, April 21st. Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Maxim Group decreased their price objective on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th.

Institutional Trading of Sensus Healthcare

Several institutional investors have recently bought and sold shares of SRTS. Opes Wealth Management LLC bought a new stake in shares of Sensus Healthcare during the third quarter worth $50,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare during the fourth quarter valued at $77,000. Jane Street Group LLC acquired a new position in shares of Sensus Healthcare during the fourth quarter valued at $79,000. Mindset Wealth Management LLC lifted its stake in shares of Sensus Healthcare by 28.1% during the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after acquiring an additional 11,000 shares during the period. Finally, Ingalls & Snyder LLC acquired a new position in shares of Sensus Healthcare during the fourth quarter valued at $219,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Price Performance

SRTS opened at $2.71 on Wednesday. Sensus Healthcare has a fifty-two week low of $2.66 and a fifty-two week high of $5.92. The business has a 50-day moving average of $3.62 and a 200-day moving average of $4.04. The company has a market capitalization of $44.61 million, a PE ratio of -5.77 and a beta of 1.09.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.The firm had revenue of $3.39 million for the quarter, compared to analysts’ expectations of $5.32 million.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.